AR057704A1 - Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto - Google Patents
Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuestoInfo
- Publication number
- AR057704A1 AR057704A1 ARP060103310A ARP060103310A AR057704A1 AR 057704 A1 AR057704 A1 AR 057704A1 AR P060103310 A ARP060103310 A AR P060103310A AR P060103310 A ARP060103310 A AR P060103310A AR 057704 A1 AR057704 A1 AR 057704A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- cycloalkyl
- pyridyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicacion 1: Un compuesto que posee la formula (1) un N-oxido, sal, o estereoisomero del mismo, donde cada línea punteada (representada por - - - - -) representa un doble enlace opcional; X es N, CH y cuando X posee un doble enlace es C; R1 es - OR11, -NH-SO2R12; R2 es hidrogeno, y cuando X es C o CH, R2 también puede ser alquilo C1-6; R3 es hidrogeno, alquilo C1-6, alcoxi C1-6-alquilo C1-6, o cicloalquilo C3-7; n es 3, 4, 5, o 6; W es un heterociclo del grupo de formulas (2); Q es N o CR4; R4 es hidrogeno; fenilo sustituido opcionalmente con alquilo C1-6 o por alcoxi C1-6; tiazolilo sustituido opcionalmente con alquilo C1-6; o piridilo; R5 es fenilo sustituido opcionalmente con alquilo C1-6 o por alcoxi C1-6; tiazolilo sustituido opcionalmente con alquilo C1-6; o piridilo; uno de R6, R7 es fenilo sustituido opcionalmente con alquilo C1-6 o con alcoxi C1-6; tiazolilo sustituido opcionalmente con alquilo C1-6; o piridilo; mientras que el otro de R6, R7 es hidrogeno; fenilo sustituido opcionalmente con alquilo C1-6 o con alcoxi C1-6; tiazolilo sustituido opcionalmente con alquilo C1-6; o piridilo; uno de R8, R9, R10 es fenilo sustituido opcionalmente con alquilo C1-6 o con alcoxi C1-6; tiazolilo sustituido opcionalmente con alquilo C1-6; o piridilo; mientras que los otros dos de R8, R9, R10 de manera independiente son hidrogeno; fenilo sustituido opcionalmente con alquilo C1-6 o con alcoxi C1-6; tiazolilo sustituido opcionalmente con alquilo C1-6; o piridilo; R11 es hidrogeno; arilo; Het; cicloalquilo C3-7 sustituido opcionalmente con alquilo C1-6; o alquilo C1-6 sustituido opcionalmente con cicloalquilo C3-7, arilo o con Het; R12 es arilo; Het; cicloalquilo C3-7 sustituido opcionalmente con alquilo C1-6; o alquilo C1-6 sustituido opcionalmente con cicloalquilo C3-7, arilo o con Het; cada arilo como grupo o parte de un grupo es fenilo, sustituido opcionalmente con uno, dos o tres sustituyentes seleccionados de halo, hidroxi, nitro, ciano, carboxilo, alquilo C1-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, alquilcarbonilo C1-6, amino, mono- o di-alquilamino C1-6, azido, mercapto, polihaloalquilo C1-6, polihaloalcoxi C1-6, cicloalquilo C3-7, pirrolidinilo, piperidinilo, piperazinilo, 4-alquil C1-6-piperazinilo, 4-alquilcarbonil C1-6-piperazinilo, morfolinilo; donde los grupos morfolinilo y piperidilo pueden ser sustituidos opcionalmente con uno o dos alquilo radicales C1-6; y cada Het como grupo o parte de un grupo es un anillo heterocíclico de 5 o 6 miembros saturado, parcialmente no saturado o completamente no saturado de 1 a 4 heteroátomos, cada uno seleccionado de manera independiente de nitrogeno, oxígeno y azufre, y estando sustituido opcionalmente con uno, dos o tres sustituyentes cada uno seleccionado de manera independiente del grupo que consiste en halo, hidroxi, nitro, ciano, carboxilo, alquilo C1-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, alquilcarbonilo C1-6 amino, mono- o di-alquilamino C1- 6, azido, mercapto, polihaloalquilo C1-6, polihaloalcoxi C1-6, cicloalquilo C3-7, pirrolidinilo, piperidinilo, piperazinilo, 4-alquil C1-6-piperazinilo, 4-alquil C1-6-carbonil-piperazinilo, morfolinilo; donde los grupos morfolinilo y piperidilo pueden estar sustituidos opcionalmente con uno o dos alquilo radicales C1-6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107072 | 2005-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057704A1 true AR057704A1 (es) | 2007-12-12 |
Family
ID=35583505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103310A AR057704A1 (es) | 2005-07-29 | 2006-07-28 | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8183277B2 (es) |
| EP (1) | EP1913015B1 (es) |
| JP (1) | JP5230416B2 (es) |
| CN (1) | CN101273052B (es) |
| AR (1) | AR057704A1 (es) |
| BR (1) | BRPI0614696A2 (es) |
| DK (1) | DK1913015T3 (es) |
| ES (1) | ES2449540T3 (es) |
| MX (1) | MX2008001402A (es) |
| MY (1) | MY142972A (es) |
| PL (1) | PL1913015T3 (es) |
| RU (1) | RU2436787C2 (es) |
| SI (1) | SI1913015T1 (es) |
| TW (1) | TWI412535B (es) |
| WO (1) | WO2007014924A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2342944T3 (es) | 2004-01-30 | 2010-07-19 | Medivir Ab | Inhibidores de ns-3 serina proteasa de vhc. |
| ATE524475T1 (de) | 2005-07-29 | 2011-09-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| JP5230416B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | Ｃ型肝炎ウイルスの大員環状阻害剤 |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CA2656816A1 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
| CN102026544A (zh) | 2007-11-14 | 2011-04-20 | 益安药业 | 大环四唑基丙型肝炎病毒丝氨酸蛋白酶抑制剂 |
| US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| MX2010008523A (es) | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
| US8372802B2 (en) | 2008-03-20 | 2013-02-12 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| CA2769652A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| JP2014506255A (ja) | 2010-12-30 | 2014-03-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | フェナントリジン大環状ｃ型肝炎セリンプロテアーゼ阻害剤 |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100187990B1 (ko) | 1992-12-29 | 1999-06-01 | 스티븐 에프. 웨인스톡 | 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체 |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| HUP0004421A3 (en) | 1996-04-23 | 2002-10-28 | Vertex Pharmaceuticals Inc Cam | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme |
| UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
| ATE283865T1 (de) | 1997-08-11 | 2004-12-15 | Boehringer Ingelheim Ca Ltd | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1964561A1 (en) | 1999-03-19 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| EP1226237A2 (en) | 1999-08-31 | 2002-07-31 | Basf Aktiengesellschaft | Method of identifying inhibitors of cdc25 |
| FR2803203B1 (fr) | 1999-12-31 | 2002-05-10 | Fournier Ind & Sante | Nouvelles formulations galeniques du fenofibrate |
| AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| IL135550A0 (en) | 2000-04-09 | 2001-05-20 | Acktar Ltd | Method and apparatus for temperature controlled vapor deposition on a substrate |
| SK14952002A3 (sk) * | 2000-04-19 | 2003-03-04 | Schering Corporation | Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| ATE461207T1 (de) | 2000-07-21 | 2010-04-15 | Schering Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
| WO2002019369A1 (fr) | 2000-08-30 | 2002-03-07 | Matsushita Electric Industrial Co., Ltd. | Unite d'affichage a plasma et son procede de fabrication |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| BRPI0116237B8 (pt) | 2000-12-18 | 2021-05-25 | Actelion Pharmaceuticals Ltd | "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina". |
| EP1404704B9 (en) | 2001-07-11 | 2008-02-20 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CN100381440C (zh) | 2002-04-11 | 2008-04-16 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂 |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| JP2007524576A (ja) * | 2003-02-07 | 2007-08-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状のｃ型肝炎セリンプロテアーゼ阻害剤 |
| ES2320771T3 (es) * | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| ES2361997T3 (es) * | 2003-09-22 | 2011-06-27 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos activos contra el virus de la hepatitis c. |
| US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2342944T3 (es) * | 2004-01-30 | 2010-07-19 | Medivir Ab | Inhibidores de ns-3 serina proteasa de vhc. |
| TWI375670B (en) | 2005-07-29 | 2012-11-01 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
| RU2419619C2 (ru) * | 2005-07-29 | 2011-05-27 | Медивир Аб | Макроциклические ингибиторы вируса гепатита с |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| EP1919904B1 (en) * | 2005-07-29 | 2014-01-08 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
| WO2007014920A1 (en) * | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| CA2617099C (en) | 2005-07-29 | 2014-03-25 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| ATE524475T1 (de) | 2005-07-29 | 2011-09-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| JP5230416B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | Ｃ型肝炎ウイルスの大員環状阻害剤 |
-
2006
- 2006-07-28 JP JP2008523380A patent/JP5230416B2/ja not_active Expired - Fee Related
- 2006-07-28 WO PCT/EP2006/064818 patent/WO2007014924A1/en active Application Filing
- 2006-07-28 AR ARP060103310A patent/AR057704A1/es unknown
- 2006-07-28 PL PL06764266T patent/PL1913015T3/pl unknown
- 2006-07-28 SI SI200631753T patent/SI1913015T1/sl unknown
- 2006-07-28 RU RU2008107726/04A patent/RU2436787C2/ru not_active IP Right Cessation
- 2006-07-28 TW TW095127604A patent/TWI412535B/zh not_active IP Right Cessation
- 2006-07-28 BR BRPI0614696-1A patent/BRPI0614696A2/pt not_active IP Right Cessation
- 2006-07-28 CN CN200680035185.3A patent/CN101273052B/zh not_active Expired - Fee Related
- 2006-07-28 MX MX2008001402A patent/MX2008001402A/es active IP Right Grant
- 2006-07-28 US US11/995,560 patent/US8183277B2/en not_active Expired - Fee Related
- 2006-07-28 ES ES06764266.0T patent/ES2449540T3/es active Active
- 2006-07-28 MY MYPI20063672A patent/MY142972A/en unknown
- 2006-07-28 EP EP06764266.0A patent/EP1913015B1/en active Active
- 2006-07-28 DK DK06764266.0T patent/DK1913015T3/en active
-
2012
- 2012-04-20 US US13/451,660 patent/US8754116B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PL1913015T3 (pl) | 2014-04-30 |
| RU2436787C2 (ru) | 2011-12-20 |
| JP2009502887A (ja) | 2009-01-29 |
| EP1913015B1 (en) | 2013-12-11 |
| RU2008107726A (ru) | 2009-09-10 |
| MY142972A (en) | 2011-01-31 |
| US20080262058A1 (en) | 2008-10-23 |
| SI1913015T1 (sl) | 2014-05-30 |
| TWI412535B (zh) | 2013-10-21 |
| CN101273052A (zh) | 2008-09-24 |
| US20120202859A1 (en) | 2012-08-09 |
| WO2007014924A1 (en) | 2007-02-08 |
| BRPI0614696A2 (pt) | 2011-04-12 |
| EP1913015A1 (en) | 2008-04-23 |
| ES2449540T3 (es) | 2014-03-20 |
| CN101273052B (zh) | 2016-01-13 |
| US8754116B2 (en) | 2014-06-17 |
| TW200728317A (en) | 2007-08-01 |
| JP5230416B2 (ja) | 2013-07-10 |
| MX2008001402A (es) | 2008-04-04 |
| US8183277B2 (en) | 2012-05-22 |
| DK1913015T3 (en) | 2014-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057704A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto | |
| AR057703A1 (es) | INHIBIDORES MACROCíCLICOS DEL VIRUS DE LA HEPATITIS C. PROCESO DE PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS. | |
| AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR055361A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR054882A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR055359A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR074758A1 (es) | Compuestos macrociclicos antivirales | |
| AR055104A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| PE20120320A1 (es) | Pirazinilpirazoles | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR084588A1 (es) | Compuesto heterociclico fusionado y su uso para el control de plagas | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| CO5721001A2 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
| AR056691A1 (es) | Derivados pirrolopirimidina como inhibidores de syk | |
| AR058439A1 (es) | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. | |
| CO6251283A2 (es) | Pirimidil ciclopentanos como inhibidores de proteina cinasa akt | |
| AR054272A1 (es) | Derivados de 3- aminopirrilidinas tri, tetra - sustituidos | |
| AR095422A1 (es) | Compuestos de piperidina sustituidos y su uso como moduladores de receptores de orexina | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |